Autologous stem cell transplantation for acute lymphocytic leukemia in adults

Hematology/Oncology Clinics of North America

Volumn 15, Issue 1, 2001, Pages 121-143

  Martin, Thomas G ^a   Linker, Charles A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MAFOSFAMIDE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK POPULATION; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0035094013     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70202-1     Document Type: Article

References (91)

1. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies
2. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
3. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: Comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction
4. Consolidative treatment of adult acute lymphoblastic leukemia: A prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation
5. Treatment of acute lymphoblastic leukemia in adults
6. Management of children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols: An update of the Ontario experience
7. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult lymphoblastic leukaemia
8. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by IL-2 in patients with acute lymphoblastic leukemia
9. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplantation
10. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission
11. Allogeneic or autologous bone marrow transplantation for acute lymphoblastic leukemia in first complete remission
12. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation
13. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant
14. Chromosomal abnormalities identify, high-risk and low-risk patients with acute lymphoblastic leukemia
15. Total body irradiation and high-dose etoposide: A new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies
16. Gene-marking to trace origin of relapse after autologous bone marrow transplant
17. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia
18. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia
19. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: A cooperative study of 62 patients
20. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation
21. Acute lymphoblastic leukemia: Recent advances in biology and therapy
22. Reconstitution of hematopoietic system with autologous marrow taken during relapse of acute myelogenous leukemia and grown in long-term culture
23. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission
24. High-dose cytosine arabinoside and total body irradiation: An improved preparative regimen for bone marrow transplantation of children with acute lymphoblastic leukemia in remission
25. Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia in first remission: Long-term results for 42 patients conditioned with an intensified regimen (TBI, high-dose Ara-C and melphalan)
26. Long-term results of autologous bone marrow transplantation in adult acute lymphoblastic leukemia
27. The role of bone marrow transplantation in adult acute lymphocytic leukemia
28. Autologous bone marrow transplantation for acute lymphoblastic leukemia
29. Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemia
30. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
31. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission
32. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
33. - positive acute lymphoblastic leukemia (ALL) included in the French multicenter trial LALA 87
34. Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy
35. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia
36. The role of allogeneic bone marrow transplantation in the treatment of high-risk acute lymphocytic leukemia in adults
37. Identical twin bone marrow transplants for leukemia
38. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings and outcome. A collaborative study of the Groupe Francais de Cytogenetique Hematologique
39. Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission
40. Etoposide, cyclophosphamide, total body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies
41. Autologous bone marrow transplantation with 4-hydroxyperoxycyclophosphamide-purged marrow for acute lymphoblastic leukemia
42. Marrow purging: Present status and future perspectives-efficacy in AML
43. Autologous bone marrow transplantation (ABMT) for acute leukemia in remission: An analysis on 1322 cases
44. Survival in adult leukemia
45. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia
46. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: Clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement
47. Hematopoietic recovery in a patient with acute lymphoblastic leukemia after an autologous marrow graft purged by combined hyperthermia and interferon in vitro
48. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies
49. Acute lymphoblastic leukemia in adults: Recent progress, future directions
50. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults
51. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission
52. Induction of graft-versus-host disease after autologous transplantation
53. Results of treatment with hyperCVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
54. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia
55. Allogeneic and autologous bone marrow transplantation for high risk acute lymphoblastic leukemia
56. Treatment with recombinant interferon a-2b early after bone marrow transplantation in patients at high risk for relapse
57. Increased efficacy in selective elimination of leukemia cell line clonogenic cells by a combination of monoclonal antibodies BA-1, BA-2, BA-3 + complement and mafosfamide
58. Risk-adapted treatment of adult acute lymphoblastic leukemia (ALL)
59. Autologous stem cell transplantation for high-risk adult acute lymphoblastic leukemia (ALL)
60. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report
61. Single versus double autologous BMT/PBSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia
62. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction
63. Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: Long-term follow-up
64. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation
65. Autologous BMT in high risk patients with CALLA-positive ALL: Possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement
66. Relapse of acute leukemia after marrow transplantation: Natural history and results of subsequent therapy
67. Adoptive immunotherapy with mismatched allogeneic peripheral blood lymphocytes (PBL) following autologous bone marrow transplantation (ABMT)
68. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 Cases from a single center
69. A comparative study of combination chemotherapy versus marrow transplant in first remission in adult acute lymphoblastic leukemia
70. Extramedullary involvement in acute lymphoblastic leukemia and its relation to therapy
71. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer
72. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft
73. Treatment of acute lymphoblastic leukemia - 30 Years' experience at St. Jude Children's Research Hospital
74. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
75. Bone marrow transplantation in first complete remission
76. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: A comparative study
77. Philadelphia positive acute lymphoblastic leukemia in adults: Age distribution, BCR breakpoint and prognostic significance
78. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia
79. Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse
80. Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia
81. Marrow transplantation for patients with acute lymphoblastic leukemia in remission
82. Autologous bone marrow transplantation in high-risk B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD 24, BA-2/CD 9, and BA-3/CD 10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging
83. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia
84. Autologous bone marrow transplantation in high risk T-Lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroxycyclophosphamide for marrow purging
85. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission
86. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia
87. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The Cancer and Leukemia Group B experience
88. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood
89. Gene rearrangements as markers of clonal variation and minimal residual disease in acute lymphoblastic leukemia
90. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia
91. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients